Most popular related searches
mutation test kit
cancer biomarker
dna derived
tissue section
cancer characterization
blood plasma
biomarker
cancerous mutation
melanoma
blood tissue
Benefits of Biocept Target Selector™ Switch-Blocker Technology
- Enrichment of cancer biomarker mutation BRAF V600E in a high wild-type background
- Suppression of wild-type DNA amplification
- Proofreading DNA Polymerase resulting in lower false positives
- Avoids damaged DNA templates (such as deaminated cytosines)
- Ultra-high sensitivity and specificity
- Combination with Sanger sequencing for orthogonal verification of the enriched mutation
- Detection of V600E as well as Wild-Type are quantitative
ctDNA Performance
- Sensitivity: 0.05% mutant allele fraction -single copy detection of mutant (~3pg DNA) in up to 14000 copies of wild-type DNA background
- Specificity: >99%
- Effective range of DNA input: 10pg-50ng DNA
FFPE DNA Performance
- Eliminates need for macrodissection of FFPE tissue by enriching mutations and blocking wild-type DNA amplification
- Sensitivity thresholds have been established to account for artifacts introduced by formaldehyde fixation
- Mutant allele frequency below this cut-off is considered negative for the mutation
- BRAF V600E cutoff: 0.46%
- Specificity: >99%
- Effective range of DNA input: 10pg-50ng DNA
These thresholds are provided as a guideline but every research facility/laboratory should establish their own thresholds based on their own criteria.
General Specifications
- Stability: 1 year
- Storage: 20°C